| Exam Code | CFA-Level-II |
| Exam Name | CFA Level II Chartered Financial Analyst |
| Questions | 715 |
| Update Date | July 16,2026 |
| Price |
Was : |
CFA-Institute CFA-Level-II exam certification is the best way to demonstrate your understanding, capability and talent. DumpsforSure is here to provide you with best knowledge on CFA-Level-II certification. By using our CFA-Level-II questions & answers you can not only secure your current position but also expedite your growth process.
We are devoted and dedicated to providing you with real and updated CFA-Level-II exam dumps, along with explanations. Keeping in view the value of your money and time, all the questions and answers on Dumpsforsure has been verified by CFA-Institute experts. They are highly qualified individuals having many years of professional experience.
Dumpsforsure is a central tool to help you prepare your CFA-Institute CFA-Level-II exam. We have collected real exam questions & answers which are updated and reviewed by professional experts regularly. In order to assist you understanding the logic and pass the CFA-Institute exams, our experts added explanation to the questions.
Dumpsforsure is committed to update the exam databases on regular basis to add the latest questions & answers. For your convenience we have added the date on the exam page showing the most latest update. Getting latest exam questions you'll be able to pass your CFA-Institute CFA-Level-II exam in first attempt easily.
Dumpsforsure is offering free Demo facility for our valued customers. You can view Dumpsforsure's content by downloading CFA-Level-II free Demo before buying. It'll help you getting the pattern of the exam and form of CFA-Level-II dumps questions and answers.
Our professional expert's team is constantly checking for the updates. You are eligible to get 90 days free updates after purchasing CFA-Level-II exam. If there will be any update found our team will notify you at earliest and provide you with the latest PDF file.
Ivan Johnson is reviewing the investment merits of BioTLab, a fast-growing biotechnology company.BioTLab has developed several drugs, which arc being licensed to major drug companies. BioTLabalso has several drugs in phase III trials (phase III trials are the last testing stage before FDAapproval). Johnson notes that two drugs recently received approval which should provide BioTLabsolid revenue growth and generate predictable cash flow well into the future. Based on the potentialfor the two drugs, BioTLab's estimated annual cash flow growth rate for the next two years is 25%,and long-term growth is expected to be 12%. Because of BioTLab's attractive investmentopportunities, the company does not pay a dividend. BioTLab's current weighted average cost ofcapital is 15% and its stock is currently trading at $50 per share. Financial information for BioTLab forthe most recent 12 months is provided below:• Net working capita! excluding cash increased from $7,460,000 to $9,985,000;• Book value increased from $81,250,000 to $101,250,000.• BioTLab currently has no debt.• Research facilities and production equipment were purchased for $8,450,000.• BioTLab held non-operating assets in the amount of $875,000.• Net income for the 12 months was $20,000,000.• BioTLab has a marginal tax rate of 40%.• Noncash charges for depreciation and restructuring for the 12 months were $1,250,000.BioTLab's management has indicated an interest in establishing a dividend and will fund new drugresearch by issuing additional debt.Johnson also reviews a competitor to BioTLab, Groh Group, which has a larger segment operating ina highly cyclical business. The Groh Group has a debt to equity ratio of 1.0 and pays no dividends. Inaddition, Groh Group plans to issue bonds in the coming year.Which of the following statements regarding free cash flow models is least likely correct?
A. Sensitivity analysis indicates that the FCFE model's valuation of BioTLab's common stock is most
sensitive to the company's growth rate.
B. FCFE is net income plus depreciation minus net capital expenditures minus the increase in working capital plus net new debt financing.
C. FCFF can be inflated by increasing capital expenditures relative to depreciation.
Ivan Johnson is reviewing the investment merits of BioTLab, a fast-growing biotechnology company.BioTLab has developed several drugs, which arc being licensed to major drug companies. BioTLabalso has several drugs in phase III trials (phase III trials are the last testing stage before FDAapproval). Johnson notes that two drugs recently received approval which should provide BioTLabsolid revenue growth and generate predictable cash flow well into the future. Based on the potentialfor the two drugs, BioTLab's estimated annual cash flow growth rate for the next two years is 25%,and long-term growth is expected to be 12%. Because of BioTLab's attractive investmentopportunities, the company does not pay a dividend. BioTLab's current weighted average cost ofcapital is 15% and its stock is currently trading at $50 per share. Financial information for BioTLab forthe most recent 12 months is provided below:• Net working capita! excluding cash increased from $7,460,000 to $9,985,000;• Book value increased from $81,250,000 to $101,250,000.• BioTLab currently has no debt.• Research facilities and production equipment were purchased for $8,450,000.• BioTLab held non-operating assets in the amount of $875,000.• Net income for the 12 months was $20,000,000.• BioTLab has a marginal tax rate of 40%.• Noncash charges for depreciation and restructuring for the 12 months were $1,250,000.BioTLab's management has indicated an interest in establishing a dividend and will fund new drugresearch by issuing additional debt.Johnson also reviews a competitor to BioTLab, Groh Group, which has a larger segment operating ina highly cyclical business. The Groh Group has a debt to equity ratio of 1.0 and pays no dividends. Inaddition, Groh Group plans to issue bonds in the coming year.Which model would be most appropriate in valuing the Groh Group?
A. FCFF model.
B. FCFE model.
C. Dividend Discount model.
Ivan Johnson is reviewing the investment merits of BioTLab, a fast-growing biotechnology company.BioTLab has developed several drugs, which arc being licensed to major drug companies. BioTLabalso has several drugs in phase III trials (phase III trials are the last testing stage before FDAapproval). Johnson notes that two drugs recently received approval which should provide BioTLabsolid revenue growth and generate predictable cash flow well into the future. Based on the potentialfor the two drugs, BioTLab's estimated annual cash flow growth rate for the next two years is 25%,and long-term growth is expected to be 12%. Because of BioTLab's attractive investmentopportunities, the company does not pay a dividend. BioTLab's current weighted average cost ofcapital is 15% and its stock is currently trading at $50 per share. Financial information for BioTLab forthe most recent 12 months is provided below:• Net working capita! excluding cash increased from $7,460,000 to $9,985,000;• Book value increased from $81,250,000 to $101,250,000.• BioTLab currently has no debt.• Research facilities and production equipment were purchased for $8,450,000.• BioTLab held non-operating assets in the amount of $875,000.• Net income for the 12 months was $20,000,000.BioTLab has a marginal tax rate of 40%.• Noncash charges for depreciation and restructuring for the 12 months were $1,250,000.BioTLab's management has indicated an interest in establishing a dividend and will fund new drugresearch by issuing additional debt.Johnson also reviews a competitor to BioTLab, Groh Group, which has a larger segment operating ina highly cyclical business. The Groh Group has a debt to equity ratio of 1.0 and pays no dividends. Inaddition, Groh Group plans to issue bonds in the coming year.If BioTLabs establishes a dividend and issues additional debt, the most likely effect on FCFF will be;
A. no effect.
B. a decrease in FCFF.
C. an increase in FCFF.
Ivan Johnson is reviewing the investment merits of BioTLab, a fast-growing biotechnology company.BioTLab has developed several drugs, which arc being licensed to major drug companies. BioTLabalso has several drugs in phase III trials (phase III trials are the last testing stage before FDAapproval). Johnson notes that two drugs recently received approval which should provide BioTLabsolid revenue growth and generate predictable cash flow well into the future. Based on the potentialfor the two drugs, BioTLab's estimated annual cash flow growth rate for the next two years is 25%,and long-term growth is expected to be 12%. Because of BioTLab's attractive investmentopportunities, the company does not pay a dividend. BioTLab's current weighted average cost ofcapital is 15% and its stock is currently trading at $50 per share. Financial information for BioTLab forthe most recent 12 months is provided below:• Net working capita! excluding cash increased from $7,460,000 to $9,985,000;• Book value increased from $81,250,000 to $101,250,000.• BioTLab currently has no debt.• Research facilities and production equipment were purchased for $8,450,000.• BioTLab held non-operating assets in the amount of $875,000.• Net income for the 12 months was $20,000,000.• BioTLab has a marginal tax rate of 40%.• Noncash charges for depreciation and restructuring for the 12 months were $1,250,000.BioTLab's management has indicated an interest in establishing a dividend and will fund new drugresearch by issuing additional debt.Johnson also reviews a competitor to BioTLab, Groh Group, which has a larger segment operating ina highly cyclical business. The Groh Group has a debt to equity ratio of 1.0 and pays no dividends. Inaddition, Groh Group plans to issue bonds in the coming year.Using a two-stage, free cash flow to the firm model, determine which of the following is closest tothe value of BioTLab.
A. $419 million.
B. $436 million.
C. $477 million.
Ivan Johnson is reviewing the investment merits of BioTLab, a fast-growing biotechnology company.BioTLab has developed several drugs, which arc being licensed to major drug companies. BioTLabalso has several drugs in phase III trials (phase III trials are the last testing stage before FDAapproval). Johnson notes that two drugs recently received approval which should provide BioTLabsolid revenue growth and generate predictable cash flow well into the future. Based on the potentialfor the two drugs, BioTLab's estimated annual cash flow growth rate for the next two years is 25%,and long-term growth is expected to be 12%. Because of BioTLab's attractive investmentopportunities, the company does not pay a dividend. BioTLab's current weighted average cost ofcapital is 15% and its stock is currently trading at $50 per share. Financial information for BioTLab forthe most recent 12 months is provided below:• Net working capita! excluding cash increased from $7,460,000 to $9,985,000;• Book value increased from $81,250,000 to $101,250,000.• BioTLab currently has no debt.• Research facilities and production equipment were purchased for $8,450,000.• BioTLab held non-operating assets in the amount of $875,000.• Net income for the 12 months was $20,000,000.• BioTLab has a marginal tax rate of 40%.• Noncash charges for depreciation and restructuring for the 12 months were $1,250,000.BioTLab's management has indicated an interest in establishing a dividend and will fund new drugresearch by issuing additional debt.Johnson also reviews a competitor to BioTLab, Groh Group, which has a larger segment operating ina highly cyclical business. The Groh Group has a debt to equity ratio of 1.0 and pays no dividends. Inaddition, Groh Group plans to issue bonds in the coming year.Johnson prefers to use free cash flow analysis to value investments. Which of the statements belowis least accurate in describing the advantages of free cash flow valuation models?
A. Accounting issues limit the usefulness of reported earnings, while free cash flow is adjusted for these issues.
B. Determining free cash flow is easier than dividends.
C. A company must generate free cash flow to grow in the long run.
Richard Grass is the healthcare analyst for Furrnon Investments and is reviewing the investmentmerits of the developing hospice industry. The hospice industry has a short history in the publicmarket, as several companies have recently completed their initial public offering. Hospice servicesare provided to patients diagnosed with terminal illness as an alternative to aggressive medicalmanagement. The use of hospice services at skilled nursing facilities and assisted-living facilities isforecasted to continue its recent growth. Medicare is the primary payer for hospice services,accounting for 85% of the approximately $7 billion in industry's revenues. Hospice providers offersymptom and pain management to patients diagnosed with a terminal illness by their physician. Theprogram was added to the Medicare benefit package in the early 1980s. Growth in the sector hasonly recently. accelerated due to the emergence of a number of for-profit companies. The caregiverprovides a plan for each admitted patient and care is given in any number of healthcareenvironments, including the patient's home.Grass's analysis of the hospice industry has uncovered several facts that are outlined below:• The industry's revenue annual growth rate has increased from 14% in the late 1990s to 25% in2008.• The average length of stay at facilities for hospice patients is increasing.• Labor costs account for 75% of total expenses, drugs 15% of total expenses, and medical supplies10%.• More than 80% of hospice patients are above 65 years old and 30% are above 85 years old.• Based on the U.S. Census Bureau's statistics, over the next six years (2009-2015), the number ofpeople in the 65 and older age group will increase annually by 1.4%.• The Medicare hospice benefit is still underutilized by the terminally ill population, according toMedPac (an independent advisory committee for the U.S. Congress on healthcare issues).• Only 30% of Medicare beneficiaries enroll in the hospice benefit before they die.• In recent years, the U.S. government has approved rate increases for the sector compared to flat ordeclining rate trends for other healthcare services.• The Medicare hospice program has a beneficiary cap which cannot exceed approximately $18,000annually per person.• The top six for-profit providers account for about half of the segment's sales.• The overall hospice provider market is roughly divided into 55% non-profit, 10% U.S. government,and 35% for-profit.Grass's analysis has narrowed his search to Hope Company. Hope controls about 7% of the totalhospice service market or 20% of the for-profit market. The company has the only regulatorapproved for-profit certificate for the state of Florida, one of the most attractive markets in theUnited States. In addition to a strong market share in Florida, Hope has a strong presence in urbanmarkets like Dallas and San Francisco. Hope has a more diversified revenue base than other publiclytraded for-profit providers.Grass is forecasting Hope Company's revenues and profits for the next year. Which of the followingstatements is least likely a risk Grass should consider in developing his forecast? FurmonInvestment's economist is forecasting a:
A. reduction in Medicare's benefit package.
B. recession for the U.S. economy.
C. larger than expected increase for healthcare labor expenditures.
Richard Grass is the healthcare analyst for Furrnon Investments and is reviewing the investmentmerits of the developing hospice industry. The hospice industry has a short history in the public market, as several companies have recently completed their initial public offering. Hospice servicesare provided to patients diagnosed with terminal illness as an alternative to aggressive medicalmanagement. The use of hospice services at skilled nursing facilities and assisted-living facilities isforecasted to continue its recent growth. Medicare is the primary payer for hospice services,accounting for 85% of the approximately $7 billion in industry's revenues. Hospice providers offersymptom and pain management to patients diagnosed with a terminal illness by their physician. Theprogram was added to the Medicare benefit package in the early 1980s. Growth in the sector hasonly recently. accelerated due to the emergence of a number of for-profit companies. The caregiverprovides a plan for each admitted patient and care is given in any number of healthcareenvironments, including the patient's home.Grass's analysis of the hospice industry has uncovered several facts that are outlined below:• The industry's revenue annual growth rate has increased from 14% in the late 1990s to 25% in2008.• The average length of stay at facilities for hospice patients is increasing.• Labor costs account for 75% of total expenses, drugs 15% of total expenses, and medical supplies10%.• More than 80% of hospice patients are above 65 years old and 30% are above 85 years old.• Based on the U.S. Census Bureau's statistics, over the next six years (2009-2015), the number ofpeople in the 65 and older age group will increase annually by 1.4%.• The Medicare hospice benefit is still underutilized by the terminally ill population, according toMedPac (an independent advisory committee for the U.S. Congress on healthcare issues).• Only 30% of Medicare beneficiaries enroll in the hospice benefit before they die.• In recent years, the U.S. government has approved rate increases for the sector compared to flat ordeclining rate trends for other healthcare services.• The Medicare hospice program has a beneficiary cap which cannot exceed approximately $18,000annually per person.• The top six for-profit providers account for about half of the segment's sales.• The overall hospice provider market is roughly divided into 55% non-profit, 10% U.S. government,and 35% for-profit.Grass's analysis has narrowed his search to Hope Company. Hope controls about 7% of the totalhospice service market or 20% of the for-profit market. The company has the only regulatorapproved for-profit certificate for the state of Florida, one of the most attractive markets in theUnited States. In addition to a strong market share in Florida, Hope has a strong presence in urbanmarkets like Dallas and San Francisco. Hope has a more diversified revenue base than other publiclytraded for-profit providers.Grass is reviewing Hope Company's pricing policy. Which of the following factors is least likely tocontribute to the company's pricing policy?
A. Hope Company relies on many different medical suppliers.
B. Hope Company provides a unique service for its customer.
C. Competitors are having difficulty entering many of Hope's key markets.
Richard Grass is the healthcare analyst for Furrnon Investments and is reviewing the investmentmerits of the developing hospice industry. The hospice industry has a short history in the publicmarket, as several companies have recently completed their initial public offering. Hospice servicesare provided to patients diagnosed with terminal illness as an alternative to aggressive medicalmanagement. The use of hospice services at skilled nursing facilities and assisted-living facilities isforecasted to continue its recent growth. Medicare is the primary payer for hospice services,accounting for 85% of the approximately $7 billion in industry's revenues. Hospice providers offersymptom and pain management to patients diagnosed with a terminal illness by their physician. Theprogram was added to the Medicare benefit package in the early 1980s. Growth in the sector hasonly recently. accelerated due to the emergence of a number of for-profit companies. The caregiver provides a plan for each admitted patient and care is given in any number of healthcareenvironments, including the patient's home.Grass's analysis of the hospice industry has uncovered several facts that are outlined below:• The industry's revenue annual growth rate has increased from 14% in the late 1990s to 25% in2008.• The average length of stay at facilities for hospice patients is increasing.• Labor costs account for 75% of total expenses, drugs 15% of total expenses, and medical supplies10%.• More than 80% of hospice patients are above 65 years old and 30% are above 85 years old.• Based on the U.S. Census Bureau's statistics, over the next six years (2009-2015), the number ofpeople in the 65 and older age group will increase annually by 1.4%.• The Medicare hospice benefit is still underutilized by the terminally ill population, according toMedPac (an independent advisory committee for the U.S. Congress on healthcare issues).• Only 30% of Medicare beneficiaries enroll in the hospice benefit before they die.• In recent years, the U.S. government has approved rate increases for the sector compared to flat ordeclining rate trends for other healthcare services.• The Medicare hospice program has a beneficiary cap which cannot exceed approximately $18,000annually per person.• The top six for-profit providers account for about half of the segment's sales.• The overall hospice provider market is roughly divided into 55% non-profit, 10% U.S. government,and 35% for-profit.Grass's analysis has narrowed his search to Hope Company. Hope controls about 7% of the totalhospice service market or 20% of the for-profit market. The company has the only regulatorapproved for-profit certificate for the state of Florida, one of the most attractive markets in theUnited States. In addition to a strong market share in Florida, Hope has a strong presence in urbanmarkets like Dallas and San Francisco. Hope has a more diversified revenue base than other publiclytraded for-profit providers.Grass's research report on Hope Company is positive on its investment merits. Grass's report states,"Hope is uniquely positioned in the hospice industry" Which of the following best supports hiscomment?
A. Hope Company's strong presence in the Florida market.
B. Hope Company relies on the Medicare program for a majority of its revenues.
C. Hope Company's diversified revenue base has allowed the company to expand beyond the hospice
sector.
Richard Grass is the healthcare analyst for Furrnon Investments and is reviewing the investmentmerits of the developing hospice industry. The hospice industry has a short history in the publicmarket, as several companies have recently completed their initial public offering. Hospice servicesare provided to patients diagnosed with terminal illness as an alternative to aggressive medicalmanagement. The use of hospice services at skilled nursing facilities and assisted-living facilities isforecasted to continue its recent growth. Medicare is the primary payer for hospice services,accounting for 85% of the approximately $7 billion in industry's revenues. Hospice providers offersymptom and pain management to patients diagnosed with a terminal illness by their physician. Theprogram was added to the Medicare benefit package in the early 1980s. Growth in the sector hasonly recently. accelerated due to the emergence of a number of for-profit companies. The caregiverprovides a plan for each admitted patient and care is given in any number of healthcareenvironments, including the patient's home.Grass's analysis of the hospice industry has uncovered several facts that are outlined below:• The industry's revenue annual growth rate has increased from 14% in the late 1990s to 25% in2008.• The average length of stay at facilities for hospice patients is increasing.• Labor costs account for 75% of total expenses, drugs 15% of total expenses, and medical supplies10%.• More than 80% of hospice patients are above 65 years old and 30% are above 85 years old.• Based on the U.S. Census Bureau's statistics, over the next six years (2009-2015), the number ofpeople in the 65 and older age group will increase annually by 1.4%.• The Medicare hospice benefit is still underutilized by the terminally ill population, according toMedPac (an independent advisory committee for the U.S. Congress on healthcare issues).• Only 30% of Medicare beneficiaries enroll in the hospice benefit before they die.• In recent years, the U.S. government has approved rate increases for the sector compared to flat ordeclining rate trends for other healthcare services.• The Medicare hospice program has a beneficiary cap which cannot exceed approximately $18,000• More than 80% of hospice patients are above 65 years old and 30% are above 85 years old.• Based on the U.S. Census Bureau's statistics, over the next six years (2009-2015), the number ofpeople in the 65 and older age group will increase annually by 1.4%.• The Medicare hospice benefit is still underutilized by the terminally ill population, according toMedPac (an independent advisory committee for the U.S. Congress on healthcare issues).• Only 30% of Medicare beneficiaries enroll in the hospice benefit before they die.• In recent years, the U.S. government has approved rate increases for the sector compared to flat ordeclining rate trends for other healthcare services.• The Medicare hospice program has a beneficiary cap which cannot exceed approximately $18,000annually per person.• The top six for-profit providers account for about half of the segment's sales.• The overall hospice provider market is roughly divided into 55% non-profit, 10% U.S. government,and 35% for-profit.Grass's analysis has narrowed his search to Hope Company. Hope controls about 7% of the totalhospice service market or 20% of the for-profit market. The company has the only regulatorapproved for-profit certificate for the state of Florida, one of the most attractive markets in theUnited States. In addition to a strong market share in Florida, Hope has a strong presence in urbanmarkets like Dallas and San Francisco. Hope has a more diversified revenue base than other publiclytraded for-profit providers.The market share of the top six for-profit providers, together with the presence of non-profit andgovernment providers, most likely indicates that the:
A. threat of new entrants is low in the hospice industry.
B. power of suppliers is low in the hospice industry.
C. threat of substitutes is high in the hospice industry.
Richard Grass is the healthcare analyst for Furrnon Investments and is reviewing the investmentmerits of the developing hospice industry. The hospice industry has a short history in the publicmarket, as several companies have recently completed their initial public offering. Hospice servicesare provided to patients diagnosed with terminal illness as an alternative to aggressive medicalmanagement. The use of hospice services at skilled nursing facilities and assisted-living facilities isforecasted to continue its recent growth. Medicare is the primary payer for hospice services,accounting for 85% of the approximately $7 billion in industry's revenues. Hospice providers offersymptom and pain management to patients diagnosed with a terminal illness by their physician. Theprogram was added to the Medicare benefit package in the early 1980s. Growth in the sector hasonly recently. accelerated due to the emergence of a number of for-profit companies. The caregiverprovides a plan for each admitted patient and care is given in any number of healthcareenvironments, including the patient's home.Grass's analysis of the hospice industry has uncovered several facts that are outlined below:• The industry's revenue annual growth rate has increased from 14% in the late 1990s to 25% in2008.• The average length of stay at facilities for hospice patients is increasing.• Labor costs account for 75% of total expenses, drugs 15% of total expenses, and medical supplies10%.• More than 80% of hospice patients are above 65 years old and 30% are above 85 years old.• Based on the U.S. Census Bureau's statistics, over the next six years (2009-2015), the number ofpeople in the 65 and older age group will increase annually by 1.4%.• The Medicare hospice benefit is still underutilized by the terminally ill population, according toMedPac (an independent advisory committee for the U.S. Congress on healthcare issues).• Only 30% of Medicare beneficiaries enroll in the hospice benefit before they die.• In recent years, the U.S. government has approved rate increases for the sector compared to flat ordeclining rate trends for other healthcare services.• The Medicare hospice program has a beneficiary cap which cannot exceed approximately $18,000annually per person.• The top six for-profit providers account for about half of the segment's sales.• The overall hospice provider market is roughly divided into 55% non-profit, 10% U.S. government,and 35% for-profit.Grass's analysis has narrowed his search to Hope Company. Hope controls about 7% of the totalhospice service market or 20% of the for-profit market. The company has the only regulatorapproved for-profit certificate for the state of Florida, one of the most attractive markets in theUnited States. In addition to a strong market share in Florida, Hope has a strong presence in urbanmarkets like Dallas and San Francisco. Hope has a more diversified revenue base than other publiclytraded for-profit providers.Grass is a firm believer in the industry life cycle. Which of the following statements is most accurateregarding the hospice industry's position in the industry life cycle? The hospice industry is in the:
A. growth stage, as indicated by recent growth in sales.
B. pioneer stage, as indicated by recent growth in sales and labor costs.
C. mature stage, as indicated by high labor costs and slow growth in the number of people aged 65
and older
